Models of Technology Transfer for Genome-Editing Technologies.

Annual Review of Genomics and Human Genetics
Gregory D Graff, Jacob S Sherkow

Abstract

Many of the fundamental inventions of genome editing, including meganucleases, zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and CRISPR, were first made at universities and patented to encourage commercial development. This gave rise to a diversity of technology transfer models but also conflicts among them. Against a broader historical and policy backdrop of university patenting and special challenges concerning research tools, we review the patent estates of genome editing and the diversity of technology transfer models employed to commercialize them, including deposit in the public domain, open access contracts, material transfer agreements, nonexclusive and exclusive licenses, surrogate licenses, and aggregated licenses. Advantages are found in this diversity, allowing experimentation and competition that we characterize as a federalism model of technology transfer. A notable feature of genome editing has been the rise and success of third-party licensing intermediaries. At the same time, the rapid pace of development of genome-editing technology is likely to erode the importance of patent estates and licensing regimes and may mitigate the effect of overly broad patents, giving rise...Continue Reading

References

Sep 1, 1989·Isis; an International Review Devoted to the History of Science and Its Cultural Influences·R D Apple
May 23, 1998·Science·M A Heller, R S Eisenberg
Jun 26, 1999·Science·M Enserink
Nov 4, 2000·Nature Biotechnology·E R Gold
Dec 4, 2001·Nature Biotechnology·G Graff, D Zilberman
Jan 29, 2002·Isis; an International Review Devoted to the History of Science and Its Cultural Influences·S S Hughes
Nov 9, 2002·Science·Christian Kilger, Kurt Bartenbach
Sep 19, 2003·The New England Journal of Medicine·David E Winickoff, Richard N Winickoff
Aug 6, 2005·Nature Biotechnology·Christopher Thomas Scott
Nov 29, 2005·Journal of Molecular Biology·Sylvain ArnouldFrédéric Pâques
Jul 15, 2006·Nature Biotechnology·Ken Garber
Mar 9, 2007·Nature Biotechnology·Charlie Schmidt
Apr 11, 2007·Nature Biotechnology·Carl Gulbrandsen
Feb 1, 1948·Annals of Surgery·C A Steiner, L H Palmer
Apr 26, 2008·Human Gene Therapy·Dirk Haussecker
Oct 11, 2008·Science·Christopher M Holman
Feb 11, 2009·Nature Biotechnology·Subhashini ChandrasekharanArti Rai
Nov 26, 2009·Science·Matthew J Moscou, Adam J Bogdanove
Jan 12, 2010·Nature Biotechnology·Cecilia L Chi-HamAlan B Bennett
Jul 28, 2010·Genetics·Michelle ChristianDaniel F Voytas
Aug 19, 2010·Nature Reviews. Genetics·Fyodor D UrnovPhilip D Gregory
Jun 10, 2011·Nature Biotechnology·Per Lundin
Oct 1, 2011·Science·Adam J Bogdanove, Daniel F Voytas
Apr 12, 2012·Nature Biotechnology·Melanie HerscovitchMelina Fan
Jun 30, 2012·Science·Martin JinekEmmanuelle Charpentier
Sep 6, 2012·Proceedings of the National Academy of Sciences of the United States of America·Giedrius GasiunasVirginijus Siksnys
Jan 5, 2013·Kennedy Institute of Ethics Journal·Audrey R Chapman, Courtney C Scala
Jan 5, 2013·Science·Le CongFeng Zhang
Jan 25, 2013·Molecular Therapy. Nucleic Acids·Dirk Haussecker
Mar 5, 2013·Annual Review of Plant Biology·Daniel F Voytas
May 7, 2013·Cell Stem Cell·Debra J H MathewsTania Bubela
May 10, 2013·Nature Biotechnology·Gregory D GraffPhilip G Pardey
Oct 8, 2013·Trends in Microbiology·Giedrius Gasiunas, Virginijus Siksnys
Aug 26, 2014·Nature Methods·Maarten HolkersManuel A F V Gonçalves
Nov 12, 2014·PLoS Biology·Joanne Kamens
Aug 8, 2015·Nature Biotechnology·David J JeffersonAlan B Bennett
Oct 8, 2015·Annual Review of Genetics·Jacob S Sherkow, Henry T Greely
Mar 10, 2016·Molecular Therapy : the Journal of the American Society of Gene Therapy·Ross Cloney

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Ribonucleases Deactivation

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on mechanisms that underlie deactivation of CRISPR ribonucleases. Here is the latest research.

CRISPR (general)

Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). CRISPR-Cas system enables the editing of genes to create or correct mutations. Discover the latest research on CRISPR here.

Related Papers

Molecular Therapy : the Journal of the American Society of Gene Therapy
Morgan L Maeder, Charles A Gersbach
Nature Reviews. Cardiology
Alanna Strong, Kiran Musunuru
Nature Reviews. Drug Discovery
Hao YinDaniel G Anderson
© 2021 Meta ULC. All rights reserved